scholarly journals Urine cytokines as biomarkers for diagnosing interstitial cystitis/bladder pain syndrome and mapping its clinical characteristics

2020 ◽  
Vol 318 (6) ◽  
pp. F1391-F1399 ◽  
Author(s):  
Yuan-Hong Jiang ◽  
Jia-Fong Jhang ◽  
Yung-Hsiang Hsu ◽  
Han-Chen Ho ◽  
Ya-Hui Wu ◽  
...  
Keyword(s):  
Interstitial Cystitis ◽  
Clinical Characteristics ◽  
Area Under The Curve ◽  
Pain Syndrome ◽  
Bladder Capacity ◽  
Bladder Pain Syndrome ◽  
Bladder Pain ◽  
Logistic Regression Models ◽  
Cytokine Profiles ◽  
Diagnostic Values

The objective of the present study was to investigate the diagnostic values of urine cytokines in patients with interstitial cystitis/bladder pain syndrome (IC/BPS) and to identify their correlations with clinical characteristics. Urine samples were collected from 127 patients with IC/BPS [European Society for the Study of Interstitial Cystitis (ESSIC) types 1 and 2] and 28 controls. Commercially available multiplex immunoassays (MILLIPLEX map kits) were used to analyze 31 targeted cytokines. Cytokine levels between patients with IC/BPS and controls were analyzed using ANOVA. Receiver-operating characteristic curves of each cytokine to distinguish IC/BPS from controls were generated for calculation of the area under the curve. Patients with IC/BPS had urine cytokine profiles that differed from those of controls. Between patients with ESSIC type 1 and 2 IC/BPS, urine cytokine profiles were also different. Among cytokines with high diagnostic values (i.e., area under the curve > 0.7) with respect to distinguish patients with ESSIC type 2 IC/BPS from controls, regulated upon activation, normal T cell expressed and presumably secreted (RANTES), macrophage inflammatory protein (MIP)-1β, and IL-8 were of higher sensitivity, whereas macrophage chemoattractant protein (MCP)-1, chemokine (C-X-C motif) ligand 10 (CXCL10), and eotaxin-1 were of higher specificity. In multivariate logistic regression models controlling for age, sex, body mass index, and diabetes mellitus, the urine cytokines with high diagnostic values (MCP-1, RANTES, CXCL10, IL-7, and eotaxin-1) remained statistically significant in differentiating IC/BPS and controls. MCP-1, CXCL10, eotaxin-1, and RANTES were positively correlated with glomerulation grade and negatively correlated with maximal bladder capacity. In conclusion, patients with IC/BPS had urine cytokine profiles that clearly differed from those of controls. Urine cytokines might be useful as biomarkers for diagnosing IC/BPS and mapping its clinical characteristics.

scholarly journals Urine biomarkers in ESSIC type 2 interstitial cystitis/bladder pain syndrome and overactive bladder with developing a novel diagnostic algorithm

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yuan-Hong Jiang ◽  
Jia-Fong Jhang ◽  
Yung-Hsiang Hsu ◽  
Han-Chen Ho ◽  
Ya-Hui Wu ◽  
...  
Keyword(s):  
Overactive Bladder ◽  
Interstitial Cystitis ◽  
Diagnostic Algorithm ◽  
Pain Syndrome ◽  
Study Groups ◽  
Bladder Pain Syndrome ◽  
Bladder Pain ◽  
Cytokine Profiles ◽  
Urine Biomarkers ◽  
Diagnostic Values

AbstractThis study aimed to investigate the diagnostic values of urine cytokines in interstitial cystitis/bladder pain syndrome (IC/BPS) and overactive bladder (OAB) patients, and to develop a novel diagnostic algorithm. Urine samples were collected from 40 IC/BPS, 40 OAB patients, and 30 controls. Commercially available multiplex immunoassays were used to analyze 31 targeted cytokines. Urine cytokine profiles were significantly different among study groups and controls. MIP-1β showed the highest sensitivity (92.2%) for identifying diseased study patients from controls. The cytokines with high diagnostic values for distinguishing between IC and OAB included IL-10, RANTES, eotaxin, CXCL10, IL-12p70, NGF, IL-6, IL-17A, MCP-1, and IL-1RA. The diagnostic algorithm was subsequently developed according to the diagnostic values obtained. MIP-1β was selected for the initial screening test to diagnose diseased patients and controls with diagnostic rates of 81.6% and 68.4%, respectively. As confirmation tests for IC/BPS, the diagnostic rates of eotaxin, CXCL10, and RANTES were 73.3%, 72.7%, and 69.7%, respectively. As the confirmation test for OAB, the diagnostic rate of IL-10 was 60%. Urine cytokine profiles of IC/BPS and OAB patients differed from those of controls and might be useful as biomarkers for diagnosis. A novel pilot diagnostic algorithm was developed based on these profiles.

scholarly journals Bladder Hydrodistention Does Not Result in a Significant Change in Bladder Capacity for Interstitial Cystitis/Bladder Pain Syndrome Patients

Urology ◽  
2019 ◽  
Vol 132 ◽  
pp. 81-86 ◽  
Author(s):  
Stephen J. Walker ◽  
Andre Plair ◽  
Kshipra Hemal ◽  
Carl D. Langefeld ◽  
Catherine Matthews ◽  
...  
Keyword(s):  
Interstitial Cystitis ◽  
Pain Syndrome ◽  
Bladder Capacity ◽  
Bladder Pain Syndrome ◽  
Bladder Pain ◽  
Significant Change

Stratification of Patients With Interstitial Cystitis/Bladder Pain Syndrome According to the Anatomical Bladder Capacity

Urology ◽  
2019 ◽  
Vol 123 ◽  
pp. 87-92 ◽  
Author(s):  
Charles Mazeaud ◽  
Jérôme Rigaud ◽  
Amélie Levesque ◽  
François-Xavier Madec ◽  
Quentin-Come Le Clerc ◽  
...  
Keyword(s):  
Interstitial Cystitis ◽  
Pain Syndrome ◽  
Bladder Capacity ◽  
Bladder Pain Syndrome ◽  
Bladder Pain

scholarly journals A nomogram for bladder pain syndrome/interstitial cystitis based on netrin-1

2021 ◽  
Author(s):  
Xiaojie Ang ◽  
Yufeng Jiang ◽  
Zongqiang Cai ◽  
Qi Zhou ◽  
Miao Li ◽  
...  
Keyword(s):  
Interstitial Cystitis ◽  
High Reliability ◽  
Area Under The Curve ◽  
Pain Syndrome ◽  
Bladder Pain Syndrome ◽  
Multivariate Logistic Regression Model ◽  
Diagnostic Model ◽  
Clinical Parameters ◽  
Lasso Regression ◽  
Bladder Pain

Abstract Purpose This study aimed to combine plasma netrin-1 and clinical parameters to construct a diagnostic model for bladder pain syndrome/interstitial cystitis (BPS/IC). Methods We analyzed the independent diagnostic value of netrin-1 and the correlation with clinical symptom scores of BPS/IC. Clinical parameters were selected using LASSO regression, and a multivariate logistic regression model based on netrin-1 was established, and then a nomogram of BPS/IC prevalence was constructed. The nomogram was evaluated using calibration curves, the C-index, and decision curve analysis (DCA). Finally, the model was validated using an internal validation method. Results The area under the curve for the ability of netrin-1 to independently predict BPS/IC diagnosis was 0.858 (p < 0.001), with a sensitivity of 85% and specificity of 82%. The predicted nomogram included three variables: age, CD3 + /CD4 + T lymphocyte ratio, and netrin-1. The C-index of this nomogram was 0.882, and the predicted values were highly consistent with the actual results in the calibration curve. In addition, the internally validated C-index of 0.870 confirms the high reliability of the model. DCA results show that the net patient benefit of the netrin-1 combined with other clinical parameters was higher than that of the single netrin-1 model. Conclusion Netrin-1 can be used as a diagnostic marker for BPS/IC and is associated with pain. The nomogram constructed by combining netrin-1 and clinical parameters was able to predict BPS/IC with great accuracy. In addition, Netrin-1 may also serve as a novel therapeutic target for BPS/IC.

scholarly journals Pelvic Floor Myofascial Pain Might Influence Treatment Outcome of Interstitial Cystitis/bladder Pain Syndrome

2021 ◽  
Author(s):  
Wan-Ru Yu ◽  
Fei-Chi Chuang ◽  
Wei-Chuan Chang ◽  
Hann-Chorng Kuo
Keyword(s):  
Pelvic Floor ◽  
Interstitial Cystitis ◽  
Myofascial Pain ◽  
Pelvic Floor Muscle ◽  
Pain Syndrome ◽  
Response Assessment ◽  
Bladder Capacity ◽  
Bladder Pain Syndrome ◽  
Bladder Pain ◽  
The Relationship

Abstract IntroductionIn patients with interstitial cystitis or bladder pain syndrome (IC/BPS), 85% were found to have pelvic floor myofascial pain (PFMP) and hypertonicity (PFH). However, they are not typically trained to consider or assess PFMP as a contributing factor to patients’ IC/BPS symptoms. This study aimed to explore the relationship between PFMP and treatment outcomes in women with IC/BPS.MethodsPatients with IC/BPS who received any type of treatment were prospectively enrolled. They underwent vaginal digital examination at baseline. PFMP severity was quantified on the visual analog scale (VAS). Subject assessment items included O’Leary-Sant symptom score (OSS), Global Response Assessment (GRA), and Beck’s anxiety inventory. Object assessment items included bladder computed tomography (CT), urodynamic parameters, maximum bladder capacity, and grade of glomerulation.ResultsA total of 65 women with IC/BPS (mean age, 57.1 ± 11.3 years) were enrolled in the study. Patients with more severe PFMP had significantly higher rate of dyspareunia (p = .031); more comorbidities (p = .010); higher number of PFMP sites (p < .001); and higher OSS (p = .012). PFMP severity was not significantly correlated with bladder conditions, whether subjective or objective. Moreover, PFMP severity (VAS) was significantly negatively associated with GRA score.ConclusionPFMP might affect the subjective results of IC/BPS treatment but not the bladder condition. Therefore, in the future treatment of patients with IC/BPS, digital vaginal examinations of pelvic floor muscles should be performed and focused more on the PFM-related conditions, and necessary PFM treatments, such as the vaginal pelvic floor muscle message, should be scheduled.

Sign in / Sign up

Export Citation Format

Share Document